Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says
Preliminary study results suggest policy tweaks may not be necessary, even as an oncology orphan product rush appears to be coming.
You may also be interested in...
Drug sponsors tell US GAO that orphan incentives don't draw them to the space, and several stakeholders say high prices and scientific discovery are the reason for the sector's growth.
US FDA's draft guidance closes loophole where sponsors could obtain an orphan designation for a pediatric subset and then be exempt from requirements to conduct pediatric studies.
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.